Alex Goldberg

Celsion Corp. (NASDAQ:CLSN) and Biogen Idec Inc. (NASDAQ:BIIB) Added to Equity Profile Report's NASDAQ Decliners Watch List

 
Repost This

Wilmington, DE -- (SBWIRE) -- 06/12/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Celsion Corp. (NASDAQ:CLSN) and Biogen Idec Inc. (NASDAQ:BIIB).

Celsion Corp. (NASDAQ:CLSN) an oncology drug development company that focuses on the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology is currently down (-10.75%) on 6,758,650 shares traded. Celsion Corp. (NASDAQ:CLSN) is currently down (-86.76%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Celsion Corp. (NASDAQ:CLSN)

Biogen Idec Inc. (NASDAQ:BIIB) a company that discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally is currently down (-5.73%) on 942,088 shares traded. Biogen Idec Inc. (NASDAQ:BIIB) is currently down (-10.93%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Biogen Idec Inc. (NASDAQ:BIIB)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com